2022
Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Kaminski M, Johung K, Boffa D. Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer. JTO Clinical And Research Reports 2022, 3: 100429. PMID: 36483656, PMCID: PMC9722471, DOI: 10.1016/j.jtocrr.2022.100429.Peer-Reviewed Original ResearchStage IV esophageal cancerNational Cancer DatabaseEsophageal cancerCancer DatabaseRadiation doseSurvival advantageMedian total radiation dosePropensity score-matched pairsOutcome of radiationRetrospective cohort studyKaplan-Meier analysisTotal radiation doseAppropriate radiation dosePalliative regimensCohort studyMedian ageRadiation administrationSurvival associationsBetter survivalPatientsLocal controlCancerDosePalliationFurther studies
2018
Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer
Mancini BR, Stein S, Lloyd S, Rutter CE, James E, Chang BW, Lacy J, Johung KL. Chemoradiation after FOLFIRINOX for borderline resectable or locally advanced pancreatic cancer. Journal Of Gastrointestinal Oncology 2018, 9: 982-988. PMID: 30603116, PMCID: PMC6286925, DOI: 10.21037/jgo.2018.04.03.Peer-Reviewed Original ResearchDistant metastasis-free survivalAdvanced pancreatic cancerConsolidative chemoradiationOverall survivalLocal controlPancreatic cancerMedian distant metastasis-free survivalCox proportional hazards modelCommon Terminology CriteriaEfficacy of FOLFIRINOXMedian overall survivalMore T4 tumorsMulti-agent chemotherapyR0 surgical resectionUse of FOLFIRINOXMonths of chemotherapyResponse Evaluation CriteriaKaplan-Meier analysisMetastasis-free survivalProportional hazards modelTerminology CriteriaProspective trialRadiographic responseSurgical resectionT3 tumors